Stifel Nicolaus Reaffirms Their Hold Rating on Zoetis (ZTS)

In a report released today, Jonathan Block from Stifel Nicolaus maintained a Hold rating on Zoetis, with a price target of $130.00.

President's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Block covers the Healthcare sector, focusing on stocks such as Zoetis, Elanco Animal Health, and Align Tech. According to TipRanks, Block has an average return of 6.8% and a 51.44% success rate on recommended stocks.

In addition to Stifel Nicolaus, Zoetis also received a Hold from Barclays’s Glen Santangelo in a report issued on February 18. However, yesterday, Morgan Stanley maintained a Buy rating on Zoetis (NYSE: ZTS).

Based on Zoetis’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.39 billion and a net profit of $603 million. In comparison, last year the company earned a revenue of $2.32 billion and had a net profit of $581 million

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZTS in relation to earlier this year. Earlier this month, Kristin Peck, the CEO of ZTS sold 20,000.00 shares for a total of $2,540,864.00.